论文部分内容阅读
目的分析莫沙必利联合舒肝解郁胶囊与单药应用治疗功能性消化不良的疗效。方法本院根据随机对照、平行、单盲的原则,选取功能性消化不良患者64例为本研究对象,其中将采用莫沙必利治疗的患者设为常规组,将采用莫沙必利联合舒肝解郁胶囊治疗的患者设为试验组,每组患者各32例。对两组患者的治疗效果以及不良反应进行比较分析。结果试验组治疗效果明显优于常规组(P<0.05)差异具备统计学意义,但两组患者的不良反应无明显差异(P>0.05)。结论在对功能性消化不良患者治疗过程中,莫沙必利联合舒肝解郁胶囊给药方式能够进一步提升整体治疗效果,同时患者不良反应少,可在临床中推广使用。
Objective To analyze the therapeutic effect of mosapride combined with Shugan Jieyu capsule and monotherapy on functional dyspepsia. Methods According to the randomized controlled, parallel and single-blind principle, we selected 64 patients with functional dyspepsia as the research object. Among them, the patients treated with mosapride were treated as the conventional group, Liver Jieyu capsule treatment of patients as the experimental group, 32 patients in each group. The two groups of patients with treatment and adverse reactions were compared. Results The treatment group was significantly better than the conventional group (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion In the treatment of patients with functional dyspepsia, mosapride combined Shugan Jieyu capsule administration can further enhance the overall treatment effect, while patients with less adverse reactions, can be used in clinical practice.